3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Breast Neoplasms
2
Anorexia
2
Depressive Disorder, Major
1
Carcinoma, Non-Small-Cell Lung
1
Cachexia
1
Advanced Cancer
1
Interventions
Nivolumab
13
Surveys and Questionnaires
6
Ipilimumab
6
linrodostat
5
Standard of Care
5
Paclitaxel
5
Bevacizumab
5
Sirolimus
4
Pemetrexed
4
Interviews as Topic
4
Gemcitabine
4
Docetaxel
4
ARRY-334543
4
temsirolimus
3
relatlimab
3
Erlotinib Hydrochloride
3
Cetuximab
3
Carboplatin
3
regorafenib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Trastuzumab
2
Sorafenib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Dasatinib
2
Cyclophosphamide
2
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Cancer
×
Mirtazapine
×
Clear all
NCT03254173
2020-02-05
MCACS100
Kasr El Aini Hospital
Phase 2/3
Completed
120 enrolled